What is Leerink Partnrs' Estimate for ABT Q2 Earnings?

Abbott Laboratories (NYSE:ABT - Free Report) - Stock analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Abbott Laboratories in a report issued on Monday, June 16th. Leerink Partnrs analyst M. Kratky anticipates that the healthcare product maker will post earnings per share of $1.26 for the quarter. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Abbott Laboratories' current full-year earnings is $5.14 per share. Leerink Partnrs also issued estimates for Abbott Laboratories' Q3 2025 earnings at $1.30 EPS, Q4 2025 earnings at $1.48 EPS, Q1 2026 earnings at $1.24 EPS, Q2 2026 earnings at $1.40 EPS, Q3 2026 earnings at $1.45 EPS, Q4 2026 earnings at $1.65 EPS, FY2026 earnings at $5.74 EPS, FY2027 earnings at $6.34 EPS, FY2028 earnings at $6.97 EPS and FY2029 earnings at $7.64 EPS.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.38 billion.

ABT has been the subject of a number of other reports. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 target price (up from $133.00) on shares of Abbott Laboratories in a research report on Thursday, April 17th. Citigroup boosted their price target on Abbott Laboratories from $135.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Morgan Stanley boosted their price target on Abbott Laboratories from $117.00 to $127.00 and gave the stock an "equal weight" rating in a research report on Thursday, April 17th. Royal Bank of Canada boosted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research report on Thursday, April 17th. Finally, Wells Fargo & Company boosted their price target on Abbott Laboratories from $136.00 to $147.00 and gave the stock an "overweight" rating in a research report on Thursday, April 17th. Six research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $142.61.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $133.99 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The stock has a 50 day moving average price of $131.70 and a 200 day moving average price of $126.58. The firm has a market capitalization of $233.12 billion, a P/E ratio of 17.51, a P/E/G ratio of 2.52 and a beta of 0.73. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $141.23.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a dividend of $0.59 per share. The ex-dividend date is Tuesday, July 15th. This represents a $2.36 annualized dividend and a yield of 1.76%. Abbott Laboratories's payout ratio is presently 30.61%.

Insider Transactions at Abbott Laboratories

In other news, Director Sally E. Blount sold 2,600 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the sale, the director now owns 34,058 shares in the company, valued at $4,415,960.28. This represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.46% of the company's stock.

Hedge Funds Weigh In On Abbott Laboratories

Large investors have recently bought and sold shares of the business. Redwood Park Advisors LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Noble Wealth Management PBC acquired a new stake in Abbott Laboratories during the fourth quarter worth $26,000. NewSquare Capital LLC increased its stake in Abbott Laboratories by 78.4% during the fourth quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after acquiring an additional 105 shares during the last quarter. Hughes Financial Services LLC purchased a new position in shares of Abbott Laboratories during the first quarter worth $27,000. Finally, WealthTrak Capital Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter worth $28,000. Institutional investors and hedge funds own 75.18% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.